Ticagrelor

Таблетки By prescription

A medicine to prevent stroke, heart attack and other conditions in people with acute coronary syndrome

Ticagrelor

Important

The drug Ticagrelor contains the active substance ticagrelor. Ticagrelor acts on blood platelets, which help blood clotting and stop bleeding. However, platelets can form blood clots inside the blood vessels of the heart and brain. This can be very dangerous because: - the clot can partially block the blood vessels leading to the heart; this reduces blood flow to the heart and can cause chest pain that "comes" and "goes" (called "unstable angina"); - the clot can completely cut off the blood supply and lead to the development of a myocardial infarction or stroke. The drug Ticagrelor belongs to the group of drugs "antithrombotic agents; antiaggregants other than heparin".

Indications

Ticagrelor is indicated for use together with acetylsalicylic acid (ASA) for the prevention of atherothrombotic complications:
- in adult patients with a history of myocardial infarction (myocardial infarction suffered 1 year or more ago) and high risk of atherothrombotic complications;
- in patients aged 50 years and older with coronary heart disease (CHD) and type 2 diabetes mellitus (DM2), without a history of myocardial infarction and/or stroke, who have undergone percutaneous coronary intervention (PCI).

Contraindications

Do not take the preparation Ticagrelor:
- If you are hypersensitive to Ticagrelor or other components of the preparation listed in point 6 of the leaflet;
- if you have pathological bleeding at the time of starting Ticagrelor;
- if you have a history of stroke caused by bleeding from the cerebral vessels;
- if you have severe liver failure;
- if you are taking any of the following medicines:
- ketoconazole (a drug to treat fungal infections);
- clarithromycin (a medicine to treat bacterial infections);
- nefazodone (a drug to treat depression);
- ritonavir or atazanavir (drugs to treat HIV and AIDS).
- If you are pregnant;
- if you are breastfeeding;
- if you are under 18 years of age.
Do not take Ticagrelor if any of the above applies to you. If you are not sure, talk to your doctor before taking this medicine.

Usage

Always use this medicine in full compliance with the recommendations of your doctor. If you have any doubts, consult your doctor.
Recommended dose
Before starting the drug Ticagrelor (in combination with ASC), patients should discontinue current antiaggregant therapy. Patients taking the drug Ticagrelor should receive daily, if there are no specific contraindications, a low maintenance dose of ASC (75-150 mg per day). When transferring patients from any prior antiaggregant therapy to Ticagrelor, the first dose should be administered within 24 hours of the last dose of another antiaggregant drug. You do not need to take a loading dose of Ticagrelor, the recommended dose is 60 mg 2 times a day (regardless of previous antiaggregant therapy and regardless of interruptions in therapy). Long-term therapy with the drug Ticagrelor is recommended, except for cases of clinical necessity in early withdrawal of the drug. There is no experience of using the drug Ticagrelor 60 mg for more than 3 years. Patients who started Ticagrelor 90 mg twice daily during treatment of acute coronary syndrome can continue therapy with Ticagrelor 60 mg twice daily without interruption after 1 year.

Download full instruction

Report undesirable reaction

If you have information about undesirable reaction after taking the drug

Hotline +7 (495) 984-28-47

Report

Have questions? Contact Us

Has contraindications. Needs specialist overview.

Please read our privacy policy

The present personal data processing policy is drawn up in accordance with the requirements of the Federal Law of July 27, 2006. No. 152-FЗ “On Personal Data” and determines the procedure for processing personal data and measures to ensure the security of personal data of Mir-Pharm LLC (hereinafter referred to as the Operator).

The operator sets as his most important goal and condition for the implementation of his activities the respect for the rights and freedoms of man and citizen in the processing of his personal data, including the protection of the rights to privacy, personal and family confidentiality.

The Operator's policy regarding the processing of personal data (hereinafter - the Policy) applies to all information that the Operator can receive about visitors of the website https://mirpharm.ru.

The user can get any clarification on issues of interest regarding the processing of his personal data by contacting the Operator via e-mail info@mirpharm.ru.

The current version of the Policy is located in free access on the Internet at https://mirpharm.ru/policy.

This document will reflect any changes in the policy of processing personal data by the Operator. The policy is valid indefinitely until it is replaced with a new version.